Neoadjuvant Immunotherapy With Chemotherapy for Stage I-IIIB Non-Small Cell Lung Cancer Patients
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
A phase II, single-arm, open-label study that assesses feasibility, safety and efficacy of
combined neoadjuvant chemotherapy and immunotherapy with PD-(L)1 inhibitor in stage I-IIIB
NSCLC adult patients followed by adjuvant PD-(L)1 inhibitor treatment for up to 1 year